Literature DB >> 19560900

Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005.

Martin Frisher1, Ilana Crome, Orsolina Martino, Peter Croft.   

Abstract

A recent systematic review concluded that cannabis use increases risk of psychotic outcomes independently of confounding and transient intoxication effects. Furthermore, a model of the association between cannabis use and schizophrenia indicated that the incidence and prevalence of schizophrenia would increase from 1990 onwards. The model is based on three factors: a) increased relative risk of psychotic outcomes for frequent cannabis users compared to those who have never used cannabis between 1.8 and 3.1, b) a substantial rise in UK cannabis use from the mid-1970s and c) elevated risk of 20 years from first use of cannabis. This paper investigates whether this has occurred in the UK by examining trends in the annual prevalence and incidence of schizophrenia and psychoses, as measured by diagnosed cases from 1996 to 2005. Retrospective analysis of the General Practice Research Database (GPRD) was conducted for 183 practices in England, Wales, Scotland and Northern Ireland. The study cohort comprised almost 600,000 patients each year, representing approximately 2.3% of the UK population aged 16 to 44. Between 1996 and 2005 the incidence and prevalence of schizophrenia and psychoses were either stable or declining. Explanations other than a genuine stability or decline were considered, but appeared less plausible. In conclusion, this study did not find any evidence of increasing schizophrenia or psychoses in the general population from 1996 to 2005.

Entities:  

Mesh:

Year:  2009        PMID: 19560900     DOI: 10.1016/j.schres.2009.05.031

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Cannabinoids for the Treatment of Movement Disorders.

Authors:  Briony Catlow; Juan Sanchez-Ramos
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

2.  Adolescent cannabis use and adult psychoticism: A longitudinal co-twin control analysis using data from two cohorts.

Authors:  Jonathan D Schaefer; Seon-Kyeong Jang; Scott Vrieze; William G Iacono; Matt McGue; Sylia Wilson
Journal:  J Abnorm Psychol       Date:  2021-09-23

3.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

4.  Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study.

Authors:  Arjen L Sutterland; Jeanne Dieleman; Jitschak G Storosum; Bettie A C Voordouw; Jojanneke Kroon; Joris Veldhuis; Damiaan A J P Denys; Lieuwe de Haan; Miriam C J M Sturkenboom
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-01-23       Impact factor: 4.328

Review 5.  Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses.

Authors:  James B Kirkbride; Antonia Errazuriz; Tim J Croudace; Craig Morgan; Daniel Jackson; Jane Boydell; Robin M Murray; Peter B Jones
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

6.  Cannabis and schizophrenia spectrum disorders: a review of clinical studies.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse
Journal:  Indian J Psychol Med       Date:  2009-07

7.  Recording of severe mental illness in United Kingdom primary care, 2000-2010.

Authors:  Sarah Hardoon; Joseph F Hayes; Ruth Blackburn; Irene Petersen; Kate Walters; Irwin Nazareth; David P J Osborn
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

8.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

9.  Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population.

Authors:  Suzanne H Gage; Stanley Zammit; Matthew Hickman
Journal:  F1000 Med Rep       Date:  2013-01-11

Review 10.  An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review.

Authors:  Jason C Simeone; Alexandra J Ward; Philip Rotella; Jenna Collins; Ricarda Windisch
Journal:  BMC Psychiatry       Date:  2015-08-12       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.